Medherant announces positive initial Phase 1 clinical trial results for testosterone patch for women
Warwick spin-out Medherant has reported positive results from its initial first-stage clinical trial at Hammersmith Medicines Research (HMR); London. The announcement comes as Menopause Awareness Month is celebrated, which focuses us on this major change in women’s lives. The technology tested - Medherant’s innovative TEPI Patch® - aims to support women through menopause by restoring testosterone to normal pre-menopausal levels.
Founded in 2014, Medherant is developing a new generation of medicinal patch technologies. Following the successful results of the pilot formulation of its testosterone the new optimised TEPI Patch® demonstrated improved testosterone delivery to post-menopausal women, successfully returning blood levels to the normal range seen in pre-menopausal women.
David Haddleton, Chief Scientific Officer at Medherant and Professor in the Department of Chemistry, University of Warwick said: “The success of this initial trial paves the way for our upcoming multiple-dose study which will start dosing before the end of the year. We remain committed to accelerating development to bring the testosterone TEPI Patch to market swiftly and to deliver the adhesion and comfort that women deserve.”
Medherant’s TEPI Patch is an innovative drug delivery system with a proprietary adhesive that gives the TEPI Patch unprecedented comfort, tolerability and adhesion. The patch is well-tolerated, leaves no residue, and is both flexible and comfortable, allowing women to wear it as they go about their normal lives. This offers a promising option for women seeking to treat a major unmet need in menopause hormone treatment.
The company has received Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee approval of its Clinical Trial Application for its next Phase 1 multiple dose pharmacokinetic study for this product. This is being developed to treat hypoactive sexual desire disorder - distressing low libido - in post-menopausal women.
“These latest results represent another major step in the development of the testosterone TEPI Patch to address a significant condition faced by many post-menopausal women,” says Karolina Afors, Medherant’s Medical Director. “Our patch technology will provide women with a superior treatment option for testosterone as part of menopause hormone therapy.”
ENDS
Notes to Editors
For more information please contact:
Matt Higgs | Media & Communications Officer (Press Office)
Email: Matt.Higgs@warwick.ac.uk | Phone: +44(0)7880 175403
About Medherant
Medherant is a clinical-stage company developing innovative treatments using its novel transdermal drug delivery technology, the TEPI Patch®. The company’s lead project is a testosterone patch for women. There is considerable interest in the transdermal delivery of drugs to overcome some of the disadvantages of oral administration, such as spikes in drug levels that can lead to side effects, and poor compliance. Patches are also a more convenient way to deliver drugs through the skin than gels and creams and provide better dose control.
About the University of Warwick
Founded in 1965, the University of Warwick is a world-leading institution known for its commitment to era-defining innovation across research and education. A connected ecosystem of staff, students and alumni, the University fosters transformative learning, interdisciplinary collaboration, and bold industry partnerships across state-of-the-art facilities in the UK and global satellite hubs. Here, spirited thinkers push boundaries, experiment, and challenge conventions to create a better world.
22 October 2025